within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX04_Ipilimumab;
model Ipilimumab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX04;

  annotation(Documentation(
    info ="<html><body><p>Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), an immune checkpoint receptor downregulating immune responses. It is used as an immunotherapy for various cancers, primarily metastatic melanoma. It is FDA and EMA approved and is currently in clinical use, either as monotherapy or in combination with other immune checkpoint inhibitors.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics reported for adults (including both sexes) with advanced or metastatic solid tumors, most often metastatic melanoma, in a 2-compartment model. Values obtained after intravenous infusion of 3 mg/kg every 3 weeks.</p><h4>References</h4><ol><li><p>Cameron, F, et al., &amp; Perry, C (2011). Ipilimumab: first global approval. <i>Drugs</i> 71(8) 1093–1104. DOI:<a href=&quot;https://doi.org/10.2165/11594010-000000000-00000&quot;>10.2165/11594010-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21668044/&quot;>https://pubmed.ncbi.nlm.nih.gov/21668044</a></p></li><li><p>Deeks, ED (2016). Pembrolizumab: A Review in Advanced Melanoma. <i>Drugs</i> 76(3) 375–386. DOI:<a href=&quot;https://doi.org/10.1007/s40265-016-0543-x&quot;>10.1007/s40265-016-0543-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26846323/&quot;>https://pubmed.ncbi.nlm.nih.gov/26846323</a></p></li><li><p>Scott, LJ (2015). Nivolumab: A Review in Advanced Melanoma. <i>Drugs</i> 75(12) 1413–1424. DOI:<a href=&quot;https://doi.org/10.1007/s40265-015-0442-6&quot;>10.1007/s40265-015-0442-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26220912/&quot;>https://pubmed.ncbi.nlm.nih.gov/26220912</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Ipilimumab;
